AnalystsCorinne JohnsonCorinne Johnson's Stock Forecasts
AnalystsCorinne Johnson
Sectors:
Analyst Ranking
Top 31%
#1619 out of 5209 analysts
Average Return
+13.32%
Win Rate
43%6 out of 14
Risk vs Reward
Poor
Good
Corinne Johnson's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Syndax Pharmaceuticals IncSNDX | +120.16% | $9.82 | $21.62 | 2025-07-09 - 2026-03-04 | Strong Buy |
Amylyx Pharmaceuticals IncAMLX | +103.65% | $7.39 | $15.05 | 2025-07-09 - 2026-03-04 | Strong Buy |
Arrivent Biopharma IncAVBP | +31.41% | $20.63 | $27.11 | 2024-02-19 - 2025-02-19 | Strong Buy |
Syndax Pharmaceuticals IncSNDX | +26.88% | $17.04 | $21.62 | 2025-09-04 - 2026-03-04 | Strong Buy |
Amylyx Pharmaceuticals IncAMLX | +25.84% | $11.96 | $15.05 | 2025-09-15 - 2026-03-04 | Strong Buy |
Corinne Johnson Analyst Color
Get additional color on Corinne Johnson's coverage of popular stocks
Corinne Johnson's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Tg Therapeutics IncTGTX | 1 | Hold | $39.00 | +33.61% | Maintains | 2 months ago |
Immunovant IncIMVT | 2 | Hold | $28.00 | +3.40% | Maintains | 3 months ago |
Mbx Biosciences IncMBX | 1 | Strong Sell | $18.00 | -42.51% | Initiates Coverage On | 3 months ago |
Amylyx Pharmaceuticals IncAMLX | 2 | Strong Buy | $20.00 | +32.89% | Maintains | 6 months ago |
Syndax Pharmaceuticals IncSNDX | 2 | Strong Buy | $24.00 | +11.01% | Maintains | 6 months ago |
Avidity Biosciences IncRNAM | 2 | Strong Buy | $55.00 | +272.88% | Reinstates | 8 months ago |
Arrivent Biopharma IncAVBP | 3 | Strong Buy | $33.00 | +24.25% | Reinstates | 8 months ago |
Neurocrine Biosciences IncNBIX | 1 | Strong Buy | $182.00 | +36.39% | Initiates Coverage On | 8 months ago |
Cg Oncology IncCGON | 3 | Strong Buy | $50.00 | N/A | Upgrades | 2 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.